R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions

FinancialNewsMedia.com News Commentary

PALM BEACH, Fla., June 29, 2022 /PRNewswire/ -- In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the development of novel therapies to treat central nervous system diseases. Regulatory guidelines and critical clinical trials are encouraging the entry of new products into the market for central nervous system therapeutic. These drugs are monitored for their efficacy, dosage, formulation, and aftereffects. A report from Grand View Research projected that the global central nervous system therapeutic market size is expected to expand at a compound annual growth rate (CAGR) of 7.4% from 2021 to 2028.  The report said: "Advancements in diagnostics and therapeutics of central nervous system (CNS) diseases are expected to increase the treatment rate globally. Moreover, the increasing prevalence of central nervous system disorders and the rising demand for effective therapeutics options are expected to boost market growth over the forecast years. According to a report published by the WHO, central nervous system disorders such as Alzheimer's disease, multiple sclerosis, epilepsy, Parkinson's disease, and stroke affect more than 1 billion people worldwide. The high unmet medical need has led all the major pharmaceutical companies to invest and develop novel therapies for the treatment of CNS diseases."  Active Companies in the markets today include SciSparc Ltd. (NASDAQ: SPRC), Denali Therapeutics Inc. (NASDAQ: DNLI), Sage Therapeutics, Inc. (NASDAQ: SAGE), Cassava Sciences, Inc. (NASDAQ: SAVA), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT).

Grand View Research continued: "The CNS therapeutics market has experienced extensive R&D efforts in the past decade, which have resulted in the introduction of novel drug-delivery systems. The advancements in the drug-delivery systems are expected to increase the adoption of a novel therapy to treat central nervous system diseases. These novel drug-delivery systems have an edge over conventional methods owing to reduced adverse effects. The demand for a novel drug-delivery system is owing to ease of delivery and availability of different dosage forms. For instance, the introduction of transdermal patches for central nervous system disorders provides an accurate amount of medicine and relief mostly for around 24 hours."